M
0.820
-0.05 (-5.61%)
| Previous Close | 0.869 |
| Open | 0.847 |
| Volume | 431,999 |
| Avg. Volume (3M) | 5,625,227 |
| Market Cap | 10,908,050 |
| Price / Book | 2.33 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -6.32 |
| Total Debt/Equity (MRQ) | 7.99% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | -23.86 M |
| Levered Free Cash Flow (TTM) | -14.36 M |
| Return on Assets (TTM) | -60.39% |
| Return on Equity (TTM) | -135.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Moleculin Biotech, Inc. | Bearish | Bearish |
AIStockmoo Score
0.3
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 3.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atticus Wealth Management, Llc | 31 Dec 2024 | 2,784 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (HC Wainwright & Co., 875.61%) | Buy |
| Median | 6.00 (631.71%) | |
| Low | 4.00 (Maxim Group, 387.81%) | Buy |
| Average | 6.00 (631.71%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Mar 2025 | 8.00 (875.61%) | Buy | 1.15 |
| 24 Mar 2025 | 8.00 (875.61%) | Buy | 1.06 | |
| Maxim Group | 25 Mar 2025 | 4.00 (387.80%) | Buy | 1.15 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |